{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T11:12:28Z","timestamp":1775560348984,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,11,28]],"date-time":"2019-11-28T00:00:00Z","timestamp":1574899200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,11,28]],"date-time":"2019-11-28T00:00:00Z","timestamp":1574899200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1007\/s11239-019-02000-x","type":"journal-article","created":{"date-parts":[[2019,11,28]],"date-time":"2019-11-28T13:03:11Z","timestamp":1574946191000},"page":"606-617","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Awareness campaigns of atrial fibrillation as an opportunity for early detection by pharmacists: an international cross-sectional study"],"prefix":"10.1007","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0562-2514","authenticated-orcid":false,"given":"Filipa Alves","family":"da Costa","sequence":"first","affiliation":[]},{"given":"Katerina","family":"Mala-Ladova","sequence":"additional","affiliation":[]},{"given":"Vivian","family":"Lee","sequence":"additional","affiliation":[]},{"given":"Salvador","family":"Tous","sequence":"additional","affiliation":[]},{"given":"John","family":"Papastergiou","sequence":"additional","affiliation":[]},{"given":"Dale","family":"Griffiths","sequence":"additional","affiliation":[]},{"given":"Marie-Camille","family":"Chaumais","sequence":"additional","affiliation":[]},{"given":"Kurt E.","family":"Hersberger","sequence":"additional","affiliation":[]},{"given":"Reka","family":"Viola","sequence":"additional","affiliation":[]},{"given":"Ema","family":"Paulino","sequence":"additional","affiliation":[]},{"given":"Trudie","family":"Lobban","sequence":"additional","affiliation":[]},{"given":"Lis","family":"Neubeck","sequence":"additional","affiliation":[]},{"given":"Ben","family":"Freedman","sequence":"additional","affiliation":[]},{"given":"Sotiris","family":"Antoniou","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2019,11,28]]},"reference":[{"key":"2000_CR1","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1161\/CIRCULATIONAHA.114.014343","volume":"131","author":"E Svennberg","year":"2015","unstructured":"Svennberg E, Engdahl J, Al-Khalili F et al (2015) Mass screening for untreated atrial fibrillation: the STROKESTOP Study. Circulation 131:2176\u20132184","journal-title":"Circulation"},{"key":"2000_CR2","doi-asserted-by":"crossref","unstructured":"Hobbs FD, Fitzmaurice DA, Mant J et al (2005) A randomised controlled trial and cost-effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 and over. The SAFE study. Health Technol Assess 9:iii\u2013x, 1\u201374","DOI":"10.3310\/hta9400"},{"key":"2000_CR3","doi-asserted-by":"publisher","first-page":"373e80","DOI":"10.1007\/s11096-010-9379-8","volume":"32","author":"GM Peterson","year":"2010","unstructured":"Peterson GM, Fitzmaurice KD, Kruup H et al (2010) Cardiovascular risk screening program in Australian community pharmacies. Pharm World Sci 32:373e80","journal-title":"Pharm World Sci"},{"key":"2000_CR4","doi-asserted-by":"publisher","first-page":"987e93","DOI":"10.1111\/j.1464-5491.2011.03296.x","volume":"28","author":"I Krass","year":"2011","unstructured":"Krass I, Mitchell B, Song YJ et al (2011) Diabetes Medication Assistance Service Stage 1: impact and sustainability of glycaemic and lipids control in patients with Type 2 diabetes. Diabet Med 28:987e93","journal-title":"Diabet Med"},{"key":"2000_CR5","doi-asserted-by":"publisher","first-page":"516e19","DOI":"10.1111\/j.1753-6405.2007.00135.x","volume":"31","author":"A Joyce","year":"2007","unstructured":"Joyce A, Berbatis CG, Sunderland VB et al (2007) Analysis of primary prevention services for cardiovascular disease in Australia\u2019s community pharmacies. Aust N Z J Public Health 31:516e19","journal-title":"Aust N Z J Public Health"},{"key":"2000_CR6","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1160\/TH14-03-0231","volume":"111","author":"N Lowres","year":"2014","unstructured":"Lowres N, Neubeck L, Salkeld G et al (2014) Feasibility and cost-effectiveness of stroke prevention through community screening for atrial fibrillation using iPhone ECG in pharmacies. The SEARCH-AF study. Thromb Haemost 111:1167\u20131176","journal-title":"Thromb Haemost"},{"key":"2000_CR7","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1007\/s11096-015-0169-1","volume":"37","author":"N Lowres","year":"2015","unstructured":"Lowres N, Krass I, Neubeck L et al (2015) Atrial fibrillation screening in pharmacies using an iPhone ECG: a qualitative review of implementation. Int J Clin Pharm 37:1111\u20131120","journal-title":"Int J Clin Pharm"},{"key":"2000_CR8","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/ijpp.12097","volume":"22","author":"J Shaw","year":"2014","unstructured":"Shaw J, Harrison J, Harrison J (2014) A community pharmacist-led anticoagulation management service: attitudes towards a new collaborative model of care in New Zealand. Int J Pharm Pract 22:397\u2013406","journal-title":"Int J Pharm Pract"},{"key":"2000_CR9","doi-asserted-by":"publisher","first-page":"e000515","DOI":"10.1136\/openhrt-2016-000515","volume":"3","author":"RK Sandhu","year":"2017","unstructured":"Sandhu RK, Dolovich L, Deif B et al (2017) High prevalence of modifiable stroke risk factors identified in a pharmacy-based screening programme. Open Heart 3:e000515","journal-title":"Open Heart"},{"issue":"4","key":"2000_CR10","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1007\/s11096-016-0303-8","volume":"38","author":"MJ Twigg","year":"2016","unstructured":"Twigg MJ, Thornley T, Scobie N (2016) Identification of patients with atrial fibrillation in UK community pharmacy: an evaluation of a new service. Int J Clin Pharm 38(4):784\u2013787","journal-title":"Int J Clin Pharm"},{"key":"2000_CR11","first-page":"377","volume":"33","author":"JJ Gomez-Doblas","year":"2012","unstructured":"Gomez-Doblas JJ, Muniz J, Alonso J et al (2012) Prevalence of atrial fibrillation in Spain. Preliminary results of the OFRECE study [abstract]. Eur Heart J 33:377","journal-title":"Eur Heart J"},{"key":"2000_CR12","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.ijcard.2012.08.002","volume":"164","author":"B Deif","year":"2013","unstructured":"Deif B, Lowres N, Freedman SB (2013) Screening for atrial fibrillation above age 65 detects an asymptomatic subset at high risk of stroke. Int J Cardiol 164:371\u2013372","journal-title":"Int J Cardiol"},{"key":"2000_CR13","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1080\/AC.67.3.2160714","volume":"67","author":"N Claes","year":"2012","unstructured":"Claes N, Van Laethem C, Goethals M et al (2012) Prevalence of atrial fibrillation in adults participating in a large-scale voluntary screening programme in Belgium. Acta Cardiol 67:273\u2013278","journal-title":"Acta Cardiol"},{"key":"2000_CR14","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","volume":"37","author":"P Kirchhof","year":"2016","unstructured":"Kirchhof P, Benussi S, Kotecha D et al (2016) 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 37:2893\u20132962","journal-title":"Eur Heart J"},{"key":"2000_CR15","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1161\/CIRCULATIONAHA.116.026693","volume":"135","author":"B Freedman","year":"2017","unstructured":"Freedman B, Camm J, Calkins H et al (2017) Screening for atrial fibrillation. Circulation 135:1851\u20131867","journal-title":"Circulation"},{"key":"2000_CR16","unstructured":"Know your pulse [instructional video]. http:\/\/www.heartrhythmalliance.org\/aa\/uk\/know-your-pulse\/. Assessed 16 June 2016"},{"key":"2000_CR17","first-page":"208","volume-title":"Constructing grounded theory: a practical guide through qualitative analysis","author":"K Charmaz","year":"2006","unstructured":"Charmaz K (2006) Constructing grounded theory: a practical guide through qualitative analysis. Sage Publication, Thousand Oaks, p 208"},{"key":"2000_CR18","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx504.P4608","author":"S Antoniou","year":"2017","unstructured":"Antoniou S, Papastergiou J, De Rango F et al (2017) Benefits of active involvement of community pharmacists in know your pulse awareness campaign. Eur Heart J. https:\/\/doi.org\/10.1093\/eurheartj\/ehx504.P4608","journal-title":"Eur Heart J"},{"key":"2000_CR19","doi-asserted-by":"publisher","first-page":"E653","DOI":"10.9778\/cmajo.20170042","volume":"5","author":"JE Tarride","year":"2017","unstructured":"Tarride JE, Dolovich L, Blackhouse G et al (2017) Screening for atrial fibrillation in Canadian pharmacies: an economic evaluation. CMAJ Open 5:E653","journal-title":"CMAJ Open"},{"key":"2000_CR20","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1160\/TH13-02-0165","volume":"110","author":"N Lowres","year":"2013","unstructured":"Lowres N, Neubeck L, Redfern J et al (2013) Screening to identify unknown atrial fibrillation. Thromb Haemost 110:213\u2013222","journal-title":"Thromb Haemost"},{"key":"2000_CR21","first-page":"130","volume":"55","author":"G Cooke","year":"2006","unstructured":"Cooke G, Doust J, Sanders S (2006) Is pulse palpation helpful in detecting atrial fibrillation? A systematic review. J Fam Pract 55:130\u2013134","journal-title":"J Fam Pract"},{"key":"2000_CR22","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.pcd.2010.05.003","volume":"4","author":"P Sookaneknun","year":"2010","unstructured":"Sookaneknun P, Saramunee K, Rattarom R et al (2010) Economic analysis of the diabetes and hypertension screening collaboration between community pharmacies and a Thai government primary care unit. Prim Care Diabetes 4:155\u2013164","journal-title":"Prim Care Diabetes"},{"key":"2000_CR23","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1093\/eurheartj\/ehi825","volume":"27","author":"J Heeringa","year":"2006","unstructured":"Heeringa J, van der Kuip DA, Hofman A et al (2006) Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 27:949\u2013953","journal-title":"Eur Heart J"},{"key":"2000_CR24","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1093\/europace\/eux177","volume":"19","author":"GH Mairesse","year":"2017","unstructured":"Mairesse GH, Moran P, Van Gelder IC et al (2017) Screening for atrial fibrillation: a European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulacion Card\u0131aca y Electrofisiolog\u0131a (SOLAECE). Europace 19:1589\u20131623","journal-title":"Europace"},{"key":"2000_CR25","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1161\/CIRCULATIONAHA.117.030583","volume":"136","author":"JP Halcox","year":"2017","unstructured":"Halcox JP, Wareham K, Cardew A et al (2017) Assessment of remote heart rhythm sampling using the AliveCor heart monitor to screen for atrial fibrillation: the REHEARSE-AF study. Circulation 136:1784\u20131794","journal-title":"Circulation"},{"key":"2000_CR26","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1007\/s11096-017-0551-2","volume":"39","author":"J Papastergiou","year":"2017","unstructured":"Papastergiou J, Kheir N, Ladova K et al (2017) Multi-national pharmacists needs assessment in the management of anticoagulation therapy: results of the International Pharmacist Anticoagulation Care Taskforce (iPACT) survey. Int J Clin Pharm 39:1282\u20131290","journal-title":"Int J Clin Pharm"},{"key":"2000_CR27","first-page":"315","volume":"43","author":"J Orchard","year":"2014","unstructured":"Orchard J, Freedman SB, Lowres N et al (2014) iPhone ECG screening by practice nurses and receptionists for atrial fibrillation in general practice: the GP-SEARCH qualitative pilot study. Aust Fam Physician 43:315\u2013319","journal-title":"Aust Fam Physician"},{"key":"2000_CR28","unstructured":"Launching our life-saving Atrial Fibrillation Pathway at EXPO2017 [News and events]. http:\/\/www.carecity.london\/news\/updates\/426-launching-our-life-saving-atrial-fibrillation-pathway-at-expo2017. Accessed 13 Aug 2018"},{"issue":"11","key":"2000_CR29","first-page":"619","volume":"91","author":"PP Rickham","year":"1964","unstructured":"Rickham PP (1964) Human experimentation. Code of Ethics of the World Medical Association. Declaration of Helsinki. Can Med Assoc J 91(11):619","journal-title":"Can Med Assoc J"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-019-02000-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11239-019-02000-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-019-02000-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,27]],"date-time":"2020-11-27T01:02:25Z","timestamp":1606438945000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11239-019-02000-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,28]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["2000"],"URL":"https:\/\/doi.org\/10.1007\/s11239-019-02000-x","relation":{},"ISSN":["0929-5305","1573-742X"],"issn-type":[{"value":"0929-5305","type":"print"},{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,28]]},"assertion":[{"value":"28 November 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"T. Lobban is the Founder and CEO of AF Assoc and Arrhythmia Alliance, a non-profit registered charity aiming to raise awareness of atrial fibrillation (AF), which receives funding from various sources, including donations, fundraising, grants, and trusts. Most of the authors are members of International Pharmacist for Anticoagulation Care Taskforce (FAC, VL, SA, MCC, DG, RV, JP, KML), an organization representing pharmacists with interests in anticoagulation, under the statutes of DRM-Foundation. DRM-Foundation has received funding in the past from Bayer Global and from Pfizer, Canada. S. Antoniou received personal fees and\/or non-financial support from Bayer, Boehringer Ingelheim, Daiichi Sankyo and BMS\/Pfizer related to AF anticoagulant management. B. Freedman reports grants to the institution, for investigator-initiated studies from Pfizer\/BMS, and Bayer and Boehringer Ingelheim personal fees and\/or non-financial support from Bayer, Boehringer Ingelheim, and BMS\/Pfizer, related to screening for AF. None of these companies had any influence on the study design, conduct or review of results presented; neither did they provide any funding for the development of the study described.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The Project was approved by Egas Moniz Ethical Review Board, Portugal (No. 319), Univerzita Karlova Eticka Komise, Czech Republic (No. 911), Barts Health NHS Trust Ethics Committee (No. 10357), the National Institute of Pharmacy and Nutrition in Hungary (No. 29517) and The Chinese University of Hong Kong Ethics Committee (CRE-2014.012). The remaining countries after consulting with their Local or National Committees, because the law mentions that as long as the activity is within the normal scope of pharmacy practice data may be used for observational studies, it was considered that the precedent decisions were valid. As an example, regulatory law for observation studies in France states that ethical approval by an Ethics Committee is not mandatory when looking at healthcare professional practices (Article R1121-1-II of the Public Health Code, Decree No. 2017-844, 9th May 2017; available at . In fact, the trend to use anonymous patient data as part of the provided care and support and acknowledge its use is being adopted in many countries by various research organisations following recommendations from patients themselves, quoting \u201cThis work uses data provided by patients and collected by the NHS as part of their care and support\u201d available at  collection was also notified to the competent bodies (e.g. Comiss\u00e3o Nacional de Prote\u00e7\u00e3o de Dados, Portugal). Patients agreeing to the EDAF gave their written consent. Only in Spain, France and Hungary were oral consent considered sufficient by the national legislation, as long as the pharmacist clearly provided all information orally, which was ensured.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The informed consent included a section authorising publication of data in a compiled and anonymized format. The investigation conforms with the principles outlined in the Declaration of Helsinki [].","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}